Company

OS Therapies

Biotechnology Research Jlabs, United States 10 employees OSTX

Employees: 10
Contacts: 2
Emails: 2
Phones: 1

www.ostherapies.com LinkedIn Crunchbase

OS Therapies Overview

Headquarters: Jlabs, United States
Website: www.ostherapies.com
Industry: Biotechnology Research
Employees: 10
Founded: 2018
Stock Symbol: OSTX
Funding: 4.2M
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)

Keywords

Oncology Osteosarcoma Pediatric Cancer Solid Tumors Ovarian Cancer Lung Cancer Breast Cancer

About OS Therapies

OS Therapies is a clinical stage research company focusing on therapeutic treatments for Osteosarcoma, Breast Cancer and other solid tumors with two platform technologies: OST-HER2 to prevent metastasis and OST-tADC to debulk solid tumors. OST-HER2 is completing a PhIIb clinical trial in 4Q2024 with significantly improved Event Free Survival (EFS), and early Overall Survival (OS). OST-tADC is a ph-sensitive novel pre-clinical Drug Conjugate that uses proprietary (IP) Silicon to cover and link the multiple payloads until they are delivered to the acidic cancer environment, dissolving the Silicon - delivering and activating the payloads.

OS Therapies Contact Details

People in AeroLeads: 4
With contact data: 2
Email contacts: 2; 50.0% coverage
Phone contacts: 1; 25.0% coverage

OS Therapies Org Chart

Sample employees and titles

Name	Title	Location	Contact
Dave Rideout	Cleared Industry Leader of Security		View
Gerald Commissiong	Chief Business Officer at Os Therapies	New York, United States	Email
Theodore Search	General Manager-ceo, Real-world Data	New York City Metropolitan Area, United States	View
Olivier Jarry	Global Life Sciences CEO, COO, CFO, Cco	New York, United States	Email Phone